Robert B. Ford - 25 Aug 2026 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Reporting relationship: CHAIRMAN AND CEO, Director
Issuer ticker: ABT
Reported as of: 25 Aug 2026
Net transaction value: -$46,204,798
SEC form: 4
Accepted by SEC: 27 Aug 2026, 17:09:42 UTC
Prior SEC filing: 03 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Robert B. Ford by Jessica H. Paik, Attorney-in-Fact

Key filing fact

Robert B. Ford filed Form 4 for ABBOTT LABORATORIES (ABT) on 27 Aug 2026.

Key facts

This page summarizes Robert B. Ford's Form 4 filing for ABBOTT LABORATORIES (ABT).
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 27 Aug 2026, 17:09.

Change

Previous filing in this sequence was filed on 03 Mar 2026.
Current net transaction value: -$46,204,798.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001612571 Primary reporting owner

Ford Robert B

Relationship: CHAIRMAN AND CEO, Director
Address: 100 ABBOTT PARK ROAD, ABBOTT PARK
Signature: /s/ Robert B. Ford by Jessica H. Paik, Attorney-in-Fact
Signature date: 27 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ABT transaction

Common shares without par value

Options Exercise

Transaction value
Shares: +151,869
Change %: +50%
Price: $44.40^*
Shares after: 458,330
Date: 25 Aug 2026
Ownership: Direct

ABT transaction

Common shares without par value

Options Exercise

Transaction value
Shares: +246,963
Change %: +54%
Price: $59.94^*
Shares after: 705,293
Date: 25 Aug 2026
Ownership: Direct

ABT transaction

Common shares without par value

Sale

Transaction value: $25,256,090
Shares: -218,535
Change %: -31%
Price: $115.57
Shares after: 486,758
Date: 25 Aug 2026
Ownership: Direct
Footnotes: F1

ABT transaction

Common shares without par value

Sale

Transaction value: $20,948,708
Shares: -180,297
Change %: -37%
Price: $116.19
Shares after: 306,461
Date: 25 Aug 2026
Ownership: Direct
Footnotes: F2

ABT holding

Common shares without par value

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 216,203
Date: 25 Aug 2026
Ownership: Ford Family Trust
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ABT transaction Derivative

Option (right to buy)

Options Exercise

Transaction value
Shares: -151,869
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 25 Aug 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 151,869
Exercise price: $44.40
Footnotes: F4

ABT transaction Derivative

Option (right to buy)

Options Exercise

Transaction value
Shares: -246,963
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 25 Aug 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 246,963
Exercise price: $59.94
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.08, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.36, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Footnote F3

Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust.

Footnote F4

Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

Footnote F5

Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.